Chronic Myeloid Leukemia

Older age at discontinuation and longer TKI therapy duration or DMR duration are significantly associated with TKI withdrawal syndrome. Higher education level and TKI discontinuation due to pregnancy or adverse events are significantly associated with psychological issues.

This study describes a novel mechanism of direct bone marrow-mediated protection of leukemic cells from imatinib/TKI, related to transfer of metabolic proteins leading to higher activity of TCA cycle, metabolic plasticity and adaptation. Targeting the stroma-driven TCA cycle-related metabolism combined with imatinib presents a promising strategy to achieve therapeutic efficacy to overcome bone marrow microenvironment-mediated protection in CML.

P2, N=40, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

P1, N=16, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2025 --> Jun 2026

Evolution in defining risk through clinical and molecular characterization should increase ability to identify emerging advanced disease, minimize progression and improve treatment of resistant chronic phase and blast phase disease. While BCR::ABL1 tyrosine kinase inhibition remains central in advanced disease, combination therapy with conventional and novel chemotherapy, immunotherapy, and allogeneic stem cell transplantation provide best long-term outcomes.

P=N/A, N=600, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> Jun 2028 | Trial primary completion date: Dec 2029 --> Jun 2028

Thus, our findings uncover a novel ERK-mTOR-axis for upregulation of proteasomal degradation of XIAP which could be targeted to overcome Imatinib-resistance by combinatorial inhibition of mTOR and XIAP in CML. This study holds the promise of a new therapeutic strategy for overcoming drug resistance in cancer.

P1, N=94, Not yet recruiting, University of Arizona

However, due to the nature and extent of the duplications, the editors no longer have confidence in the results and conclusions reported in the paper. The co-authors, F. Zhang, H. Ni, X. Li and H. Liu did not respond to our notice of retraction.

Bulk and single-cell RNAseq followed by functional validation and in silico analysis showed that CLF treatment is associated with apoptosis, ER stress, oxidative phosphorylation, and mitochondrial dysfunction. Most importantly, CLF modulates the expression of several non-coding RNAs, including MALAT1 and NEAT1, that are linked to tumor cell proliferation, cell migration, and drug resistance.

P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Not yet recruiting --> Recruiting

Reversine modulates genomic stability in CML cells through dual mechanisms involving Aurora kinase inhibition and telomere architecture remodeling. The integration of 3D telomere profiling highlights reversine's potential as a therapeutic agent targeting nuclear disorganization and mitotic dysregulation in leukemia.